Swindled Swindled

S10 Ep143: The New Formula (Abbott Laboratories)

Sep 10, 2026 · 1h 14m

Summary

This episode of Swindled investigates the 2025 infant botulism outbreak linked to By Heart formula, a startup that rose to prominence during the 2022 national formula shortage. The narrative traces how By Heart capitalized on the crisis caused by Abbott Laboratories’ Sturgis plant shutdown, which resulted from egregious sanitation failures and a Cronobacter contamination. The episode details Abbott’s history of regulatory negligence, including ignored whistleblower reports and a pattern of prioritizing stock buybacks over safety, which precipitated the initial shortage. It concludes by exam…

Topics discussed

Sponsors: Progressive and Dupixent Rose Dexter's illness and the search for a safe formula Founding By Heart and the challenges of the formula industry By Heart's rise during the 2022 national formula shortage By Heart botulism recall and subsequent lawsuits Investigation into By Heart contamination and industry flaws Introduction to Abbott Laboratories and the 2022 crisis Sponsor: Home Chef Sponsors: Progressive and Dupixent Cronobacter outbreak and Abbott's massive recall The worsening shortage and FDA inspection of Sturgis plant Inconclusive FDA findings and government emergency measures The 'perfect storm' of bureaucratic delays and vulnerabilities Sponsor: Swindled Valued Listener Rewards Program Sponsors: Blueland and Progressive Sponsor: Dupixent Whistleblower complaints and ignored safety warnings FDA's slow response and pandemic-era inspection gaps Abbott's profits, stock buybacks, and OSHA complaints History of Cronobacter issues and infant deaths Criminal investigations and Abbott's past scandals Pharmaceutical fraud settlements and kickback schemes The PediaSure litigation and corporate business model WIC contracts, market dominance, and lobbying efforts Sponsor: Gusto Sponsors: Progressive and Dupixent Robin Gill's story and NEC in premature infants Scientific debate on formula and NEC risk Abbott's defense strategy and the Gill trial The $495 million verdict and appellate rulings Dropped criminal charges and FDA leadership concerns Outro and listener support information Sponsor: Iris Palmer Sponsor: OxyClean
Listen ad-free on Castria